NCT00692263

The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of Southern Denmark · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and pharmacodynamic(PD) measurements are done for the next 24 hours. It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is seen in Pk or PK of tramadol

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	escitalopram and tramadol	10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
DRUG	placebo	placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
DRUG	placebo and tramadol	9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9

Timeline

• Start date: 2008-02-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2008-06-06
• Last updated: 2008-09-10

Locations

1 site across 1 country: Denmark